Cargando…
Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice
Vaccine and antiviral development against SARS-CoV-2 infection or COVID-19 disease would benefit from validated small animal models. Here, we show that transgenic mice expressing human angiotensin-converting enzyme 2 (hACE2) by the human cytokeratin 18 promoter (K18 hACE2) represent a susceptible ro...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705712/ https://www.ncbi.nlm.nih.gov/pubmed/33257679 http://dx.doi.org/10.1038/s41467-020-19891-7 |
_version_ | 1783617001016524800 |
---|---|
author | Oladunni, Fatai S. Park, Jun-Gyu Pino, Paula A. Gonzalez, Olga Akhter, Anwari Allué-Guardia, Anna Olmo-Fontánez, Angélica Gautam, Shalini Garcia-Vilanova, Andreu Ye, Chengjin Chiem, Kevin Headley, Colwyn Dwivedi, Varun Parodi, Laura M. Alfson, Kendra J. Staples, Hilary M. Schami, Alyssa Garcia, Juan I. Whigham, Alison Platt, Roy Neal Gazi, Michal Martinez, Jesse Chuba, Colin Earley, Stephanie Rodriguez, Oscar H. Mdaki, Stephanie Davis Kavelish, Katrina N. Escalona, Renee Hallam, Cory R. A. Christie, Corbett Patterson, Jean L. Anderson, Tim J. C. Carrion, Ricardo Dick, Edward J. Hall-Ursone, Shannan Schlesinger, Larry S. Alvarez, Xavier Kaushal, Deepak Giavedoni, Luis D. Turner, Joanne Martinez-Sobrido, Luis Torrelles, Jordi B. |
author_facet | Oladunni, Fatai S. Park, Jun-Gyu Pino, Paula A. Gonzalez, Olga Akhter, Anwari Allué-Guardia, Anna Olmo-Fontánez, Angélica Gautam, Shalini Garcia-Vilanova, Andreu Ye, Chengjin Chiem, Kevin Headley, Colwyn Dwivedi, Varun Parodi, Laura M. Alfson, Kendra J. Staples, Hilary M. Schami, Alyssa Garcia, Juan I. Whigham, Alison Platt, Roy Neal Gazi, Michal Martinez, Jesse Chuba, Colin Earley, Stephanie Rodriguez, Oscar H. Mdaki, Stephanie Davis Kavelish, Katrina N. Escalona, Renee Hallam, Cory R. A. Christie, Corbett Patterson, Jean L. Anderson, Tim J. C. Carrion, Ricardo Dick, Edward J. Hall-Ursone, Shannan Schlesinger, Larry S. Alvarez, Xavier Kaushal, Deepak Giavedoni, Luis D. Turner, Joanne Martinez-Sobrido, Luis Torrelles, Jordi B. |
author_sort | Oladunni, Fatai S. |
collection | PubMed |
description | Vaccine and antiviral development against SARS-CoV-2 infection or COVID-19 disease would benefit from validated small animal models. Here, we show that transgenic mice expressing human angiotensin-converting enzyme 2 (hACE2) by the human cytokeratin 18 promoter (K18 hACE2) represent a susceptible rodent model. K18 hACE2 transgenic mice succumbed to SARS-CoV-2 infection by day 6, with virus detected in lung airway epithelium and brain. K18 ACE2 transgenic mice produced a modest TH1/2/17 cytokine storm in the lung and spleen that peaked by day 2, and an extended chemokine storm that was detected in both lungs and brain. This chemokine storm was also detected in the brain at day 6. K18 hACE2 transgenic mice are, therefore, highly susceptible to SARS-CoV-2 infection and represent a suitable animal model for the study of viral pathogenesis, and for identification and characterization of vaccines (prophylactic) and antivirals (therapeutics) for SARS-CoV-2 infection and associated severe COVID-19 disease. |
format | Online Article Text |
id | pubmed-7705712 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-77057122020-12-03 Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice Oladunni, Fatai S. Park, Jun-Gyu Pino, Paula A. Gonzalez, Olga Akhter, Anwari Allué-Guardia, Anna Olmo-Fontánez, Angélica Gautam, Shalini Garcia-Vilanova, Andreu Ye, Chengjin Chiem, Kevin Headley, Colwyn Dwivedi, Varun Parodi, Laura M. Alfson, Kendra J. Staples, Hilary M. Schami, Alyssa Garcia, Juan I. Whigham, Alison Platt, Roy Neal Gazi, Michal Martinez, Jesse Chuba, Colin Earley, Stephanie Rodriguez, Oscar H. Mdaki, Stephanie Davis Kavelish, Katrina N. Escalona, Renee Hallam, Cory R. A. Christie, Corbett Patterson, Jean L. Anderson, Tim J. C. Carrion, Ricardo Dick, Edward J. Hall-Ursone, Shannan Schlesinger, Larry S. Alvarez, Xavier Kaushal, Deepak Giavedoni, Luis D. Turner, Joanne Martinez-Sobrido, Luis Torrelles, Jordi B. Nat Commun Article Vaccine and antiviral development against SARS-CoV-2 infection or COVID-19 disease would benefit from validated small animal models. Here, we show that transgenic mice expressing human angiotensin-converting enzyme 2 (hACE2) by the human cytokeratin 18 promoter (K18 hACE2) represent a susceptible rodent model. K18 hACE2 transgenic mice succumbed to SARS-CoV-2 infection by day 6, with virus detected in lung airway epithelium and brain. K18 ACE2 transgenic mice produced a modest TH1/2/17 cytokine storm in the lung and spleen that peaked by day 2, and an extended chemokine storm that was detected in both lungs and brain. This chemokine storm was also detected in the brain at day 6. K18 hACE2 transgenic mice are, therefore, highly susceptible to SARS-CoV-2 infection and represent a suitable animal model for the study of viral pathogenesis, and for identification and characterization of vaccines (prophylactic) and antivirals (therapeutics) for SARS-CoV-2 infection and associated severe COVID-19 disease. Nature Publishing Group UK 2020-11-30 /pmc/articles/PMC7705712/ /pubmed/33257679 http://dx.doi.org/10.1038/s41467-020-19891-7 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Oladunni, Fatai S. Park, Jun-Gyu Pino, Paula A. Gonzalez, Olga Akhter, Anwari Allué-Guardia, Anna Olmo-Fontánez, Angélica Gautam, Shalini Garcia-Vilanova, Andreu Ye, Chengjin Chiem, Kevin Headley, Colwyn Dwivedi, Varun Parodi, Laura M. Alfson, Kendra J. Staples, Hilary M. Schami, Alyssa Garcia, Juan I. Whigham, Alison Platt, Roy Neal Gazi, Michal Martinez, Jesse Chuba, Colin Earley, Stephanie Rodriguez, Oscar H. Mdaki, Stephanie Davis Kavelish, Katrina N. Escalona, Renee Hallam, Cory R. A. Christie, Corbett Patterson, Jean L. Anderson, Tim J. C. Carrion, Ricardo Dick, Edward J. Hall-Ursone, Shannan Schlesinger, Larry S. Alvarez, Xavier Kaushal, Deepak Giavedoni, Luis D. Turner, Joanne Martinez-Sobrido, Luis Torrelles, Jordi B. Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice |
title | Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice |
title_full | Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice |
title_fullStr | Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice |
title_full_unstemmed | Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice |
title_short | Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice |
title_sort | lethality of sars-cov-2 infection in k18 human angiotensin-converting enzyme 2 transgenic mice |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705712/ https://www.ncbi.nlm.nih.gov/pubmed/33257679 http://dx.doi.org/10.1038/s41467-020-19891-7 |
work_keys_str_mv | AT oladunnifatais lethalityofsarscov2infectionink18humanangiotensinconvertingenzyme2transgenicmice AT parkjungyu lethalityofsarscov2infectionink18humanangiotensinconvertingenzyme2transgenicmice AT pinopaulaa lethalityofsarscov2infectionink18humanangiotensinconvertingenzyme2transgenicmice AT gonzalezolga lethalityofsarscov2infectionink18humanangiotensinconvertingenzyme2transgenicmice AT akhteranwari lethalityofsarscov2infectionink18humanangiotensinconvertingenzyme2transgenicmice AT allueguardiaanna lethalityofsarscov2infectionink18humanangiotensinconvertingenzyme2transgenicmice AT olmofontanezangelica lethalityofsarscov2infectionink18humanangiotensinconvertingenzyme2transgenicmice AT gautamshalini lethalityofsarscov2infectionink18humanangiotensinconvertingenzyme2transgenicmice AT garciavilanovaandreu lethalityofsarscov2infectionink18humanangiotensinconvertingenzyme2transgenicmice AT yechengjin lethalityofsarscov2infectionink18humanangiotensinconvertingenzyme2transgenicmice AT chiemkevin lethalityofsarscov2infectionink18humanangiotensinconvertingenzyme2transgenicmice AT headleycolwyn lethalityofsarscov2infectionink18humanangiotensinconvertingenzyme2transgenicmice AT dwivedivarun lethalityofsarscov2infectionink18humanangiotensinconvertingenzyme2transgenicmice AT parodilauram lethalityofsarscov2infectionink18humanangiotensinconvertingenzyme2transgenicmice AT alfsonkendraj lethalityofsarscov2infectionink18humanangiotensinconvertingenzyme2transgenicmice AT stapleshilarym lethalityofsarscov2infectionink18humanangiotensinconvertingenzyme2transgenicmice AT schamialyssa lethalityofsarscov2infectionink18humanangiotensinconvertingenzyme2transgenicmice AT garciajuani lethalityofsarscov2infectionink18humanangiotensinconvertingenzyme2transgenicmice AT whighamalison lethalityofsarscov2infectionink18humanangiotensinconvertingenzyme2transgenicmice AT plattroyneal lethalityofsarscov2infectionink18humanangiotensinconvertingenzyme2transgenicmice AT gazimichal lethalityofsarscov2infectionink18humanangiotensinconvertingenzyme2transgenicmice AT martinezjesse lethalityofsarscov2infectionink18humanangiotensinconvertingenzyme2transgenicmice AT chubacolin lethalityofsarscov2infectionink18humanangiotensinconvertingenzyme2transgenicmice AT earleystephanie lethalityofsarscov2infectionink18humanangiotensinconvertingenzyme2transgenicmice AT rodriguezoscarh lethalityofsarscov2infectionink18humanangiotensinconvertingenzyme2transgenicmice AT mdakistephaniedavis lethalityofsarscov2infectionink18humanangiotensinconvertingenzyme2transgenicmice AT kavelishkatrinan lethalityofsarscov2infectionink18humanangiotensinconvertingenzyme2transgenicmice AT escalonarenee lethalityofsarscov2infectionink18humanangiotensinconvertingenzyme2transgenicmice AT hallamcoryra lethalityofsarscov2infectionink18humanangiotensinconvertingenzyme2transgenicmice AT christiecorbett lethalityofsarscov2infectionink18humanangiotensinconvertingenzyme2transgenicmice AT pattersonjeanl lethalityofsarscov2infectionink18humanangiotensinconvertingenzyme2transgenicmice AT andersontimjc lethalityofsarscov2infectionink18humanangiotensinconvertingenzyme2transgenicmice AT carrionricardo lethalityofsarscov2infectionink18humanangiotensinconvertingenzyme2transgenicmice AT dickedwardj lethalityofsarscov2infectionink18humanangiotensinconvertingenzyme2transgenicmice AT hallursoneshannan lethalityofsarscov2infectionink18humanangiotensinconvertingenzyme2transgenicmice AT schlesingerlarrys lethalityofsarscov2infectionink18humanangiotensinconvertingenzyme2transgenicmice AT alvarezxavier lethalityofsarscov2infectionink18humanangiotensinconvertingenzyme2transgenicmice AT kaushaldeepak lethalityofsarscov2infectionink18humanangiotensinconvertingenzyme2transgenicmice AT giavedoniluisd lethalityofsarscov2infectionink18humanangiotensinconvertingenzyme2transgenicmice AT turnerjoanne lethalityofsarscov2infectionink18humanangiotensinconvertingenzyme2transgenicmice AT martinezsobridoluis lethalityofsarscov2infectionink18humanangiotensinconvertingenzyme2transgenicmice AT torrellesjordib lethalityofsarscov2infectionink18humanangiotensinconvertingenzyme2transgenicmice |